The acquisition enhances Chiltern's Oncology, Biopharma and Source offerings, broadens its therapeutic expertize
Chiltern has completed its acquisition of Theorem Clinical Research, strengthening its position as the largest mid-sized provider of comprehensive clinical development services.
Chiltern now comprises 3,700 people across 47 countries, expanding its footprint in Europe, North America and Asia-Pacific. The acquisition enhances Chiltern's Oncology, Biopharma and Source offerings, broadens its therapeutic expertize and establishes new capabilities in medical device and diagnostics, clinical analytics and clinical supplies.
"By bringing Chiltern and Theorem together, we have created a unique, mid-sized research partner focused on providing exceptional scientific expertise and personal service. Clients can expect the same high level of service, now with expanded capabilities. Senior leadership will still be involved in running trials," said Dr Jim Esinhart, CEO, Chiltern.
"The acquisition of Theorem marks an important milestone for Chiltern. We stayed true to our mission to be a responsive, client-centric mid-sized provider, yet we enhanced our geographic coverage and service offerings in key areas. We are delighted to welcome the dynamic Theorem team to Chiltern and are pleased to announce that Dr John Potthoff, Theorem's president and CEO, has joined our board as a non-executive director," said Mr Nick Thornton, chairman, Chiltern.